Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.1B

May4Mon

Post-Earnings Recap

ReportedQ1-2026After Close4:30 PM EDT

CRISPR Therapeutics AG Misses on EPS, Stock Up 3.78%

Metric	Actual	Expected	Surprise
EPS	$-1.28	N/A	-12.38%
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

CRISPR Therapeutics AG Misses on EPS, Stock Up 3.78%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.28	N/A	-12.38%
Revenue	N/A	N/A	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based on numerical results only.

What It Means

CRISPR Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.78%. This could indicate that investors are looking beyond the EPS miss, possibly due to other factors not disclosed in the earnings call.

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines for serious diseases. Operating in the healthcare sector, it aims to leverage CRISPR technology to create innovative therapies, which could significantly impact treatment options for genetic disorders and other conditions.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

R&D Spending

Research and development spending is crucial for biotech firms like CRISPR, as it reflects their commitment to innovation and future product pipelines.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q4 2025, CRISPR reported an EPS of -$1.37, which was worse than analysts' expectations, leading to a slight stock increase the following day. The company continues to face challenges in meeting revenue expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's mixed performance in previous quarters. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If CRISPR can demonstrate significant progress in its clinical trials or better-than-expected R&D efficiency, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to provide updates on key trials or continues to report larger-than-expected losses, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials?

Investors will be closely watching for any news that could indicate the potential success of upcoming therapies, as this could significantly impact the company's future.

How is the company managing its R&D expenditures in light of recent financial losses?

Understanding how CRISPR is allocating its resources will be crucial for assessing its strategy and potential for recovery.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of CRISPR's ongoing clinical trials, which could yield positive results not reflected in current expectations.

Supporting Evidence

The options market is pricing an 11.29% move, indicating higher volatility expectations than historical averages.

The company's recent history shows a mixed EPS surprise rate, suggesting that the market may be overly cautious.

Previous quarters have shown that positive surprises can lead to significant stock movements, which may not be fully accounted for.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CRISPR's innovative approach will translate into successful products, with recent performance raising concerns.

Bull Confirmed If

Positive updates on clinical trials that indicate a high likelihood of success could validate the bull case.

Bear Confirmed If

Continued losses and lack of progress in trials could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.29%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±11.3% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

59.1%

Calls (179K)P/C Ratio: 0.77Puts (55K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 6 of 19 (32%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 19 (68%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.5%, with a raw directional average of +3.2% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations with positive clinical trial updates, history suggests the stock could rise around 1.2% on average the next day.

In-Line / Cautious

If results are in line but management expresses caution, the stock might see a muted reaction as investors digest the commentary.

Miss

A miss on earnings could lead to a decline of about 1.8% on average, as seen in previous quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key clinical trials and any preliminary results.
2Details on R&D spending and how it aligns with the company's strategic goals.
3Management's outlook on future product launches and their potential market impact.
4Any partnerships or collaborations that could enhance the company's capabilities.
5Insights into how the company plans to address recent financial challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

R&D Spending

Research and development spending is crucial for biotech firms like CRISPR, as it reflects their commitment to innovation and future product pipelines.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's mixed performance in previous quarters. The lack of analyst estimates adds uncertainty to expectations.

Bull Case

If CRISPR can demonstrate significant progress in its clinical trials or better-than-expected R&D efficiency, it could lead to a positive market reaction.

Bear Case

Conversely, if the company fails to provide updates on key trials or continues to report larger-than-expected losses, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials?

Investors will be closely watching for any news that could indicate the potential success of upcoming therapies, as this could significantly impact the company's future.

How is the company managing its R&D expenditures in light of recent financial losses?

Understanding how CRISPR is allocating its resources will be crucial for assessing its strategy and potential for recovery.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of CRISPR's ongoing clinical trials, which could yield positive results not reflected in current expectations.

Supporting Evidence

The options market is pricing an 11.29% move, indicating higher volatility expectations than historical averages.

The company's recent history shows a mixed EPS surprise rate, suggesting that the market may be overly cautious.

Previous quarters have shown that positive surprises can lead to significant stock movements, which may not be fully accounted for.

Key Risk

If clinical trial results exceed expectations, it could shift market sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CRISPR's innovative approach will translate into successful products, with recent performance raising concerns.

Bull Confirmed If

Positive updates on clinical trials that indicate a high likelihood of success could validate the bull case.

Bear Confirmed If

Continued losses and lack of progress in trials could confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±11.29%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±11.3% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

59.1%

Calls (179K)P/C Ratio: 0.77Puts (55K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 6 of 19 (32%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations with positive clinical trial updates, history suggests the stock could rise around 1.2% on average the next day.

In-Line / Cautious

If results are in line but management expresses caution, the stock might see a muted reaction as investors digest the commentary.

Miss

A miss on earnings could lead to a decline of about 1.8% on average, as seen in previous quarters.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of key clinical trials and any preliminary results.
2Details on R&D spending and how it aligns with the company's strategic goals.
3Management's outlook on future product launches and their potential market impact.
4Any partnerships or collaborations that could enhance the company's capabilities.
5Insights into how the company plans to address recent financial challenges.